Bradley A. McGregor

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi, Meng Xiao He, Ziad Bakouny et al. · Cancer Cell · 2021 · 628 citations · Full text

Medicine, Immunology, Oncology +17

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 626 citations · Full text

Medicine, Oncology, Pharmacology +17

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

David A. Braun, Kelly Street, Kelly P. Burke et al. · Cancer Cell · 2021 · 517 citations · Full text

Medicine, Immunology, Oncology +15

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 451 citations

Medicine, Oncology, Surgery +16

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell et al. · The Lancet Oncology · 2021 · 267 citations

Medicine, Oncology, Pharmacology +14